Functional characterization of factor V-Ile359Thr: A novel mutation associated with thrombosis

Blood

Volumn 103, Issue 9, 2004, Pages 3381-3387

  Steen, Mårten ^b   Norstrøm, Eva A ^b   Tholander, Ann Louise ^b   Bolton Maggs, Paula H B ^b   Mumford, Andrew ^b   McVey, John H ^b   Tuddenham, Edward G D ^b   Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; ASPARAGINE; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; CARBOHYDRATE; GLYCINE; ISOLEUCINE; PROCOAGULANT; PROTEIN S; THREONINE; VALINE;

ARTICLE; GENE EXPRESSION; MOLECULAR BIOLOGY; MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SITE DIRECTED MUTAGENESIS; STATISTICAL SIGNIFICANCE; THROMBOSIS; WESTERN BLOTTING; WILD TYPE;

EID: 1942425200     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2092     Document Type: Article

References (33)

1. Tracy PB, Eide LL, Bowie EJ, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60:59-63,
2. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326-330.
3. Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988;71:539-555.
4. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry. 1990;29:1118-1128.
5. Suzuki K, Dahlback B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982;257:6556-6564.
6. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
7. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem. 1994;269:18735-18738.
8. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost. 1996;76:208-214.
9. Thorelli E, Kaufman RJ, Dahlback B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood. 1999;93:2552-2558.
10. van Wljk R, Nieuwenhuis K, van den Berg M, et al. Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood. 2001;98:358-367.
11. Ajzner EE, Balogh I, Szabo T, Marosi A, Haramura G, Muszbek L. Severe coagulation factor V deficiency caused by 2 novel frameshift mutations: 2952deIT in exon 13 and 5493insG in exon 16 of factor 5 gene. Blood. 2002;99:702-705.
12. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
13. Dahlback B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost. 1999;25:273-289.
14. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood. 1998;91:1140-1144.
15. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998;91:1135-1139.
16. Shen MC, Lin JS, Tsay W. Factor V Arg306→Gly mutation is not associated with activated protein C resistance and is rare in Taiwanese Chinese. Thromb Haemost. 2001;85:270-273.
17. Franco RF, Maffei FH, Lourenco D, et al. Factor V Arg306→Thr (factor V Cambridge) and factor V Arg306→Gly mutations in venous thrombotic disease. Br J Haematol. 1998;103:888-890.
18. Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002;100:524-530.
19. Mumford AD, McVey JH, Morse CV, et al. Factor V 1359T: a novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol. 2003;123:496-501.
20. Jenny R, Pittman D, Toole J, et al. Complete cDNA and derived amino acid sequence of human FV. Proc Natl Acad Sci USA. 1987;84:4846-4850.
21. Dahlback B. Human coagluation factor V purification and thrombin-catalyzed activation. J Clin Invest. 1980;66:583-591.
22. Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood. 1991;77:2641-2648.
23. Dahlback B, Hildebrand B, Malm J. Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. J Biol Chem. 1990;265:8127-8135.
24. Böttcher CJF. A rapid and sensitive sub-micro phosphorus determination. Anal Chim Acta. 1961;24:203-207.
25. Kaufman RJ. Vectors used for expression in mammalian cells. Methods Enzymol. 1990;185:487-511.
26. Steen M, Dahlback B. Thrombin-mediated proteolysis of factor V resulting In gradual B-domain release and exposure of the factor Xa-binding site. J Biol Chem. 2002;277:38424-38430.
27. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270:21158-21166.
28. Steen M, Villoutreix BO, Norstrom EA, Yamazaki T, Dahlback B. Defining the factor Xa-binding site on factor Va by site-directed glycosylation. J Biol Chem. 2002;277:50022-50029.
29. Heeb MJ, Kojima Y, Hackeng TM, Griffin JH. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci. 1996;5:1883-1889.
30. Walker FJ, Scandella D, Fay PJ. Identification of the binding site for activated protein C on the light chain of factors V and VIII. J Biol Chem. 1990;265:1484-1489.
31. Villoutreix BO, Dahlback B. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci. 1998;7:1317-1325.
32. Dahlback B. Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC rasistance) causes hypercoagulability by dual mechanisms. J Lab Clin Med. 1999;133:415-422.
33. Thorelli E. Mechanisms that regulate the anticoagulant function of coagulation factor V. Scand J Clin Lab Invest Suppl. 1999;229:19-26.